MedTrace Logo

Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD

NCT00291408 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-08-07

No results posted yet for this study

Summary

The purpose of the study is to compare histone acetyltransferase (HAT) and histone deacetylase (HDAC) expressions and activities in induced sputum macrophages obtained from patients with moderate to severe COPD and age-matched normal non-smokers

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Age Matched Healthy Volunteers (Non-smokers)

Interventions

PROCEDURE

Skin Prick Test

PROCEDURE

Impulse Oscillometry

PROCEDURE

Exhaled Nitric Oxide

PROCEDURE

Spirometry

PROCEDURE

Reversibility

PROCEDURE

Exhaled Breath Condensate

PROCEDURE

Sputum Induction

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Peter J Barnes, MA DM DSc FRCP · Imperial College London

  • Kazuhiro Ito, PhD · Imperial College London

  • Ian Adcock, PhD · Imperial College London

  • Sergei A Kharitonov, MD PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291408 on ClinicalTrials.gov